Cargando…

Use of MIRUS™ for MAC-driven application of isoflurane, sevoflurane, and desflurane in postoperative ICU patients: a randomized controlled trial

BACKGROUND: The MIRUS™ (TIM, Koblenz, Germany) is an electronical gas delivery system, which offers an automated MAC (minimal alveolar concentration)-driven application of isoflurane, sevoflurane, or desflurane, and can be used for sedation in the intensive care unit. We investigated its consumption...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellgardt, Martin, Georgevici, Adrian Iustin, Klutzny, Mitja, Drees, Dominik, Meiser, Andreas, Gude, Philipp, Vogelsang, Heike, Weber, Thomas Peter, Herzog-Niescery, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795651/
https://www.ncbi.nlm.nih.gov/pubmed/31620921
http://dx.doi.org/10.1186/s13613-019-0594-8
_version_ 1783459486061559808
author Bellgardt, Martin
Georgevici, Adrian Iustin
Klutzny, Mitja
Drees, Dominik
Meiser, Andreas
Gude, Philipp
Vogelsang, Heike
Weber, Thomas Peter
Herzog-Niescery, Jennifer
author_facet Bellgardt, Martin
Georgevici, Adrian Iustin
Klutzny, Mitja
Drees, Dominik
Meiser, Andreas
Gude, Philipp
Vogelsang, Heike
Weber, Thomas Peter
Herzog-Niescery, Jennifer
author_sort Bellgardt, Martin
collection PubMed
description BACKGROUND: The MIRUS™ (TIM, Koblenz, Germany) is an electronical gas delivery system, which offers an automated MAC (minimal alveolar concentration)-driven application of isoflurane, sevoflurane, or desflurane, and can be used for sedation in the intensive care unit. We investigated its consumption of volatile anesthetics at 0.5 MAC (primary endpoint) and the corresponding costs. Secondary endpoints were the technical feasibility to reach and control the MAC automatically, the depth of sedation at 0.5 MAC, and awakening times. Mechanically ventilated and sedated patients after major surgery were enrolled. Upon arrival in the intensive care unit, patients obtained intravenous propofol sedation for at least 1 h to collect ventilation and blood gas parameters, before they were switched to inhalational sedation using MIRUS™ with isoflurane, sevoflurane, or desflurane. After a minimum of 2 h, inhalational sedation was stopped, and awakening times were recorded. A multivariate electroencephalogram and the Richmond Agitation Sedation Scale (RASS) were used to assess the depth of sedation. Vital signs, ventilation parameters, gas consumption, MAC, and expiratory gas concentrations were continuously recorded. RESULTS: Thirty patients obtained inhalational sedation for 18:08 [14:46–21:34] [median 1st–3rd quartiles] hours. The MAC was 0.58 [0.50–0.64], resulting in a Narcotrend Index of 37.1 [30.9–42.4] and a RASS of − 3.0 [− 4.0 to (− 3.0)]. The median gas consumption was significantly lowest for isoflurane ([ml h(−1)]: isoflurane: 3.97 [3.61–5.70]; sevoflurane: 8.91 [6.32–13.76]; and desflurane: 25.88 [20.38–30.82]; p < 0.001). This corresponds to average costs of 0.39 € h(−1) for isoflurane, 2.14 € h(−1) for sevoflurane, and 7.54 € h(−1) for desflurane. Awakening times (eye opening [min]: isoflurane: 9:48 [4:15–20:18]; sevoflurane: 3:45 [0:30–6:30]; desflurane: 2:00 [1:00–6:30]; p = 0.043) and time to extubation ([min]: isoflurane: 10:10 [8:00–20:30]; sevoflurane: 7:30 [4:37–14:22]; desflurane: 3:00 [3:00–6:00]; p = 0.007) were significantly shortest for desflurane. CONCLUSIONS: A target-controlled, MAC-driven automated application of volatile anesthetics is technically feasible and enables an adequate depth of sedation. Gas consumption was highest for desflurane, which is also the most expensive volatile anesthetic. Although awakening times were shortest, the actual time saving of a few minutes might be negligible for most patients in the intensive care unit. Thus, using desflurane seems not rational from an economic perspective. Trial registration Clinical Trials Registry (ref.: NCT03860129). Registered 24 September 2018—Retrospectively registered.
format Online
Article
Text
id pubmed-6795651
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-67956512019-10-24 Use of MIRUS™ for MAC-driven application of isoflurane, sevoflurane, and desflurane in postoperative ICU patients: a randomized controlled trial Bellgardt, Martin Georgevici, Adrian Iustin Klutzny, Mitja Drees, Dominik Meiser, Andreas Gude, Philipp Vogelsang, Heike Weber, Thomas Peter Herzog-Niescery, Jennifer Ann Intensive Care Research BACKGROUND: The MIRUS™ (TIM, Koblenz, Germany) is an electronical gas delivery system, which offers an automated MAC (minimal alveolar concentration)-driven application of isoflurane, sevoflurane, or desflurane, and can be used for sedation in the intensive care unit. We investigated its consumption of volatile anesthetics at 0.5 MAC (primary endpoint) and the corresponding costs. Secondary endpoints were the technical feasibility to reach and control the MAC automatically, the depth of sedation at 0.5 MAC, and awakening times. Mechanically ventilated and sedated patients after major surgery were enrolled. Upon arrival in the intensive care unit, patients obtained intravenous propofol sedation for at least 1 h to collect ventilation and blood gas parameters, before they were switched to inhalational sedation using MIRUS™ with isoflurane, sevoflurane, or desflurane. After a minimum of 2 h, inhalational sedation was stopped, and awakening times were recorded. A multivariate electroencephalogram and the Richmond Agitation Sedation Scale (RASS) were used to assess the depth of sedation. Vital signs, ventilation parameters, gas consumption, MAC, and expiratory gas concentrations were continuously recorded. RESULTS: Thirty patients obtained inhalational sedation for 18:08 [14:46–21:34] [median 1st–3rd quartiles] hours. The MAC was 0.58 [0.50–0.64], resulting in a Narcotrend Index of 37.1 [30.9–42.4] and a RASS of − 3.0 [− 4.0 to (− 3.0)]. The median gas consumption was significantly lowest for isoflurane ([ml h(−1)]: isoflurane: 3.97 [3.61–5.70]; sevoflurane: 8.91 [6.32–13.76]; and desflurane: 25.88 [20.38–30.82]; p < 0.001). This corresponds to average costs of 0.39 € h(−1) for isoflurane, 2.14 € h(−1) for sevoflurane, and 7.54 € h(−1) for desflurane. Awakening times (eye opening [min]: isoflurane: 9:48 [4:15–20:18]; sevoflurane: 3:45 [0:30–6:30]; desflurane: 2:00 [1:00–6:30]; p = 0.043) and time to extubation ([min]: isoflurane: 10:10 [8:00–20:30]; sevoflurane: 7:30 [4:37–14:22]; desflurane: 3:00 [3:00–6:00]; p = 0.007) were significantly shortest for desflurane. CONCLUSIONS: A target-controlled, MAC-driven automated application of volatile anesthetics is technically feasible and enables an adequate depth of sedation. Gas consumption was highest for desflurane, which is also the most expensive volatile anesthetic. Although awakening times were shortest, the actual time saving of a few minutes might be negligible for most patients in the intensive care unit. Thus, using desflurane seems not rational from an economic perspective. Trial registration Clinical Trials Registry (ref.: NCT03860129). Registered 24 September 2018—Retrospectively registered. Springer International Publishing 2019-10-16 /pmc/articles/PMC6795651/ /pubmed/31620921 http://dx.doi.org/10.1186/s13613-019-0594-8 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research
Bellgardt, Martin
Georgevici, Adrian Iustin
Klutzny, Mitja
Drees, Dominik
Meiser, Andreas
Gude, Philipp
Vogelsang, Heike
Weber, Thomas Peter
Herzog-Niescery, Jennifer
Use of MIRUS™ for MAC-driven application of isoflurane, sevoflurane, and desflurane in postoperative ICU patients: a randomized controlled trial
title Use of MIRUS™ for MAC-driven application of isoflurane, sevoflurane, and desflurane in postoperative ICU patients: a randomized controlled trial
title_full Use of MIRUS™ for MAC-driven application of isoflurane, sevoflurane, and desflurane in postoperative ICU patients: a randomized controlled trial
title_fullStr Use of MIRUS™ for MAC-driven application of isoflurane, sevoflurane, and desflurane in postoperative ICU patients: a randomized controlled trial
title_full_unstemmed Use of MIRUS™ for MAC-driven application of isoflurane, sevoflurane, and desflurane in postoperative ICU patients: a randomized controlled trial
title_short Use of MIRUS™ for MAC-driven application of isoflurane, sevoflurane, and desflurane in postoperative ICU patients: a randomized controlled trial
title_sort use of mirus™ for mac-driven application of isoflurane, sevoflurane, and desflurane in postoperative icu patients: a randomized controlled trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795651/
https://www.ncbi.nlm.nih.gov/pubmed/31620921
http://dx.doi.org/10.1186/s13613-019-0594-8
work_keys_str_mv AT bellgardtmartin useofmirusformacdrivenapplicationofisofluranesevofluraneanddesfluraneinpostoperativeicupatientsarandomizedcontrolledtrial
AT georgeviciadrianiustin useofmirusformacdrivenapplicationofisofluranesevofluraneanddesfluraneinpostoperativeicupatientsarandomizedcontrolledtrial
AT klutznymitja useofmirusformacdrivenapplicationofisofluranesevofluraneanddesfluraneinpostoperativeicupatientsarandomizedcontrolledtrial
AT dreesdominik useofmirusformacdrivenapplicationofisofluranesevofluraneanddesfluraneinpostoperativeicupatientsarandomizedcontrolledtrial
AT meiserandreas useofmirusformacdrivenapplicationofisofluranesevofluraneanddesfluraneinpostoperativeicupatientsarandomizedcontrolledtrial
AT gudephilipp useofmirusformacdrivenapplicationofisofluranesevofluraneanddesfluraneinpostoperativeicupatientsarandomizedcontrolledtrial
AT vogelsangheike useofmirusformacdrivenapplicationofisofluranesevofluraneanddesfluraneinpostoperativeicupatientsarandomizedcontrolledtrial
AT weberthomaspeter useofmirusformacdrivenapplicationofisofluranesevofluraneanddesfluraneinpostoperativeicupatientsarandomizedcontrolledtrial
AT herzogniesceryjennifer useofmirusformacdrivenapplicationofisofluranesevofluraneanddesfluraneinpostoperativeicupatientsarandomizedcontrolledtrial